Evaluation of the 3p21.3 tumour-suppressor gene cluster

Oncogene

Volumn 26, Issue 52, 2007, Pages 7283-7301

  Hesson, L B ^a,b   Cooper, W N ^b   Latif, F ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

3p21.3; Epigenetics; RASSFIA; Tumor suppressor gene

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CISPLATIN; DOXORUBICIN;

101F6 GENE; BILE DUCT CARCINOMA; BLADDER CANCER; BLU GENE; BREAST CANCER; CACNA2D2 GENE; CANCER DIAGNOSIS; CANCER GENETICS; CANCER GROWTH; DNA METHYLATION; EPIGENETICS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FUS1 GENE; GENE; GENE CLUSTER; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENETIC ASSOCIATION; HOMOZYGOSITY; HUMAN; HYAL2 GENE; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MEDULLOBLASTOMA; NONHUMAN; NPR2L GENE; NUCLEOTIDE SEQUENCE; PL6 GENE; PRIORITY JOURNAL; PROMOTER REGION; RASSF1 GENE; REVIEW; STOMACH CANCER; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

CHROMOSOMES, HUMAN, PAIR 3; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS;

EID: 36148946432     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210547     Document Type: Review

References (120)

1. Abe M, Ohira M, Kaneda A, Yagi Y, Yamamoto S, Kitano Y et al. (2005). CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res 65: 828-834.
2. Agathanggelou A, Bieche I, Ahmed-Choudhury J, Nicke B, Dammann R, Baksh S et al. (2003a). Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma. Cancer Res 63: 5344-5351.
3. Agathanggelou A, Cooper WN, Latif F. (2005). Role of the ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 65: 3497-3508.
4. Agathanggelou A, Dallol A, Zochbauer-Muller S, Morrissey C, Honorio S, Hesson L et al. (2003b). Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers. Oncogene 22: 1580-1588.
5. Ahmed-Choudhury J, Agathanggelou A, Fenton SL, Ricketts C, Clark GJ, Maher ER et al. (2005). Transcriptional regulation of cyclin A2 by RASSF1A through the enhanced binding of p120E4F to the cyclin A2 promoter. Cancer Res 65: 2690-2697.
6. Akino K, Toyota M, Suzuki H, Mita H, Sasaki Y, Ohe-Toyota M et al. (2005). The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology 129: 156-169.
7. Alden KJ, Garcia J. (2001). Differential effect of gabapentin on neuronal and muscle calcium currents. J Pharmacol Exp Ther 297: 727-735.
8. Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, Lenny N et al. (2001). ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol 21: 6470-6483.
9. Anantharaman V, Aravind L. (2000). Cache - a signaling domain common to animal Ca(2+)-channel subunits and a class of prokaryotic chemotaxis receptors. Trends Biochem Sci 25: 535-537.
10. Aoyama Y, Avruch J, Zhang XF. (2004). Norel inhibits tumor cell growth independent of Ras or the MST1/2 kinases. Oncogene 23: 3426-3433.
11. 2+ pump 4b and the proapoptotic tumor suppressor Ras-associated factor 1 (RASSF1). J Biol Chem 279: 31318-31328.
12. Bais AJ, Gardner AE, McKenzie OL, Callen DF, Sutherland GR, Kremmidiotis G. (2004). Aberrant CBFA2T3B gene promoter methylation in breast tumors. Mol Cancer 3: 22.
13. Baksh S, Tommasi S, Fenton S, Yu VC, Martins LM, Pfeifer GP et al. (2005). The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to bax conformational change and cell death. Mol Cell 18: 637-650.
14. Barclay J, Balaguero N, Mione M, Ackerman SL, Letts VA, Brodbeck J et al. (2001). Ducky mouse phenotype of epilepsy and ataxia is associated with mutations in the Cacna2d2 gene and decreased calcium channel current in cerebellar Purkinje cells. J Neurosci 21: 6095-6104.
15. Bertrand P, Courel MN, Maingonnat C, Jardin F, Tilly H, Bastard C. (2005). Expression of HYAL2 mRNA, hyaluronan and hyaluronidase in B-cell non-Hodgkin lymphoma: relationship with tumor aggressiveness. Int J Cancer 113: 207-212.
16. Bourguignon LY, Singleton PA, Diedrich F, Stern R, Gilad E. (2004). CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem 279: 26991-27007.
17. Brena RM, Plass C, Costello JF. (2006). Mining methylation for early detection of common cancers. PLoS Med 3: e479.
18. Brodbeck J, Davies A, Courtney JM, Meir A, Balaguero N, Canti C et al. (2002). The ducky mutation in Cacna2d2 results in altered Purkinje cell morphology and is associated with the expression of a truncated alpha 2 delta-2 protein with abnormal function. J Biol Chem 277: 7684-7693.
19. Carboni GL, Gao BN, Nishizaki M, Xu K, Minna JD, Roth JA et al. (2003). CACNA2D2-mediated apoptosis in NSCLC cells is associated with alterations of the intracellular calcium signaling and disruption of mitochondria membrane integrity. Oncogene 22: 615-626.
20. Chen JD, Lui WO, Vos MD, Clark GJ, Takahashi M, Schoumans J et al. (2003). The t(1;3) breakpoint-spanning involved in clear cell renal cell genes LSAMP and NORE1 are carcinomas. Cancer Cell 4: 405-413.
21. Chow LS, Lo KW, Kwong J, To KF, Tsang KS, Lam CW et al. (2004a). RASSF1A is a target tumor suppressor from 3p21 in nasopharyngeal carcinoma. Int J Cancer 109 839-847.
22. Chow LS, Lo KW, Kwong J, Wong AYH, Huang DP. (2004b). Aberrant methylation of RASSF4/AD037 in nasopharyngeal carcinoma. Oncol Rep 12: 781-787.
23. Csoka AB, Frost GI, Stern R. (2001). The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol 20: 499-508.
24. Csoka AB, Scherer SW, Stern R. (1999). Expression analysis of six paralogous human hyaluronidase genes clustered on chromosomes 3p21 and 7q31. Genomics 60: 356-361.
25. Dallol A, Agathanggelou A, Fenton SL, Ahmed-Choudhury J, Hesson L, Vos MD et al. (2004). RASSFIA interacts with microtubule-associated proteins and modulates microtubule dynamics. Cancer Res 64: 4112-4116.
26. Dallol A, Agathanggelou A, Tommasi S, Pfeifer GP, Maher ER, Latif F. (2005). Involvement of the RASSF1A tumor suppressor gene in controlling cell migration. Cancer Res 65: 7653-7659.
27. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. (2000). Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25: 315-319.
28. Danilkovitch-Miagkova A, Duh FM, Kuzmin I, Angeloni D, Liu SL, Miller AD et al. (2003). Hyaluronidase 2 negatively regulates RON receptor tyrosine kinase and mediates transformation of epithelial cells by jaagsiekte sheep retrovirus. Proc Natl Acad Sci USA 100: 4580-4585.
29. De las Heras M, Barsky SH, Hasleton P, Wagner M, Larson E, Egan J et al. (2000). Evidence for a protein related immunologically to the jaagsiekte sheep retrovirus in some human lung tumours. Eur Respir J 16: 330-332.
30. Eckfeld K, Hesson L, Vos MD, Bieche I, Latif F, Clark GJ. (2004). RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family. Cancer Res 64: 8688-8693.
31. Endoh M, Tamura G, Honda T, Homma N, Terashima M, Nishizuka S et al. (2005). RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. Br J Cancer 93: 1395-1399.
32. Enegd B, King JA, Stylli S, Paradiso L, Kaye AH, Novak U. (2002). Overexpression of hyaluronan synthase-2 reduces the tumorigenic potential of glioma cells lacking hyaluronidase activity. Neurosurgery 50: 1311-1318.
33. Falvella FS, Manenti G, Spinola M, Pignatiello C, Conti B, Pastorino U et al. (2006). Identification of RASSF8 as a candidate lung tumor suppressor gene. Oncogene 25: 3934-3938.
34. Fenton SL, Dallol A, Agathanggelou A, Hesson L, Ahmed-Choudhury J, Baksh S et al. (2004). Identification of the E1A-regulated transcription factor p120(E4F) as an interacting partner of the RASSF1A candidate tumor suppressor gene. Cancer Res 64: 102-107.
35. Fischer WH, Schubert D. (1996). Characterization of a novel platelet-derived growth factor-associated protein. J Neurochem 66: 2213-2216.
36. Fletcher CF, Tottene A, Lennon VA, Wilson SM, Dubel SJ, Paylor R et al. (2001). Dystonia and cerebellar atrophy in Cacna1a null mice lacking P/Q calcium channel activity. FASEB J 15: 1288-1290.
37. Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, Clark SJ. (2006). Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet 38: 540-549.
38. Gao B, Sekido Y, Maximov A, Saad M, Forgacs E, Latif F et al. (2000). Functional properties of a new voltage-dependent calcium channel alpha(2)delta auxiliary subunit gene (CACNA2D2). J Biol Chem 275: 12237-12242.
39. Gopalan B, Ito I, Branch CD, Stephens C, Roth JA, Ramesh R. (2004). Nanoparticle based systemic gene therapy for lung cancer: molecular mechanisms and strategies to suppress nanoparticle-mediated inflammatory response. Technol Cancer Res Treat 3: 647-657.
40. 2+ channel alpha 2 delta subunit in current stimulation and subunit interaction. Neuron 16: 431-440.
41. Harjes E, Harjes S, Wohlgemuth S, Muller KH, Krieger E, Herrmann C et al. (2006). GTP-Ras disrupts the intramolecular complex of C1 and RA domains of Nore1. Structure 14: 881-888.
42. Hateboer G, Gennissen A, Ramos YF, Kerkhoven RM, Sonntag-Buck V, Stunnenberg HG et al. (1995). BS69, a novel adenovirus E1A-associated protein that inhibits E1A transactivation. EMBO J 14: 3159-3169.
43. Hesson L, Bieche I, Krex D, Criniere E, Hoang-Xuan K, Maher ER et al. (2004). Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene 23: 2408-2419.
44. Hesson L, Dallol A, Minna JD, Maher ER, Latif F. (2003). NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene 22: 947-954.
45. Hesson LB, Cooper WN, Latif F. (2007). The role of RASSF1A methylation in cancer. Dis Markers 23: 73-87.
46. Hesson LB, Wilson R, Morton D, Adams C, Walker M, Maher ER et al. (2005). CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene 24: 3987-3994.
47. Hung J, Kishimoto Y, Sugio K, Virmani A, McIntire DD, Minna JD et al. (1995). Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA 273: 1908.
48. Irimia M, Fraga MF, Sanchez-Cespedes M, Esteller M. (2004). CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer. Oncogene 23: 8695-8699.
49. Ito I, Ji L, Tanaka F, Saito Y, Gopalan B, Branch CD et al. (2004). Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther 11: 733-739.
50. Ito M, Ito G, Kondo M, Uchiyama M, Fukui T, Mori S et al. (2005). Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer. Cancer Lett 225: 131-139.
51. Ivanov SV, Ward JM, Tessarollo L, McAreavey D, Sachdev V, Fananapazir L et al. (2004). Cerebellar ataxia, seizures, premature death, and cardiac abnormalities in mice with targeted disruption of the Cacna2d2 gene. Am J Pathol 165: 1007-1018.
52. Ji L, Nishizaki M, Gao B, Burbee D, Kondo M, Kamibayashi C et al. (2002). Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res 62: 2715-2720.
53. Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, Zhang XF et al. (2002). Identification of a novel Ras-regulated proapoptotic pathway. Curr Biol 12: 253-265.
54. Kitagawa D, Kajiho H, Negishi T, Ura S, Watanabe T, Wada T et al. (2006). Release of RASSF1C from the nucleus by Daxx degradation links DNA damage and SAPK/JNK activation. EMBO J 25: 3286-3297.
55. Klugbauer N, Lacinova L, Marais E, Hobom M, Hofmann F. (1999). Molecular diversity of the calcium channel alpha2-delta subunit. J Neurosci 19: 684-691.
56. Kochetkova M, McKenzie OL, Bais AJ, Martin JM, Secker GA, Seshadri R et al. (2002). CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3. Cancer Res 62: 4599-4604.
57. Kok K, Naylor SL, Buys CH. (1997). Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv Cancer Res 71: 27-92.
58. Kondo M, Ji L, Kamibayashi C, Tomizawa Y, Randle D, Sekido Y et al. (2001). Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells. Oncogene 20: 6258-6262.
59. Ladendorff NE, Wu S, Lipsick JS. (2001). BS69, an adenovirus E1A-associated protein, inhibits the transcriptional activity of c-Myb. Oncogene 20: 125-132.
60. Lai HC, Lin YW, Chang CC, Wang HC, Chu TW, Yu MH et al. (2006). Hypermethylation of two consecutive tumor suppressor genes, BLU and RASSF1A, located at 3p21.3 in cervical neoplasias. Gynecol Oncol (in press).
61. LeBoeuf RD, Ban EM, Green MM, Stone AS, Propst SM, Blalock JE et al. (1998). Molecular cloning, sequence analysis, expression, and tissue distribution of suppressin, a novel suppressor of cell cycle entry. J Biol Chem 273: 361-368.
62. Lepperdinger G, Mullegger J, Kreil G. (2001). Hyal2 - less active, but more versatile? Matrix Biol 20: 509-514.
63. Lepperdinger G, Strobl B, Kreil G. (1998). HYAL2, a human gene expressed in many cells, encodes a lysosomal hyaluronidase with a novel type of specificity. J Biol Chem 273: 22466-22470.
64. Lerman MI, Minna JD. (2000). The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. Cancer Res 60: 6116-6133.
65. Li F, Wang F, Haraldson K, Protopopov A, Duh FM, Geil L et al. (2004a). Functional characterization of the candidate tumor suppressor gene NPRL2/G21 located in 3p21.3C. Cancer Res 64: 6438-6443.
66. Li JF, Wang FL, Protopopov A, Malyukova A, Kashuba V, Minna JD et al. (2004b). Inactivation of RASSF1C during in vivo tumor growth identifies it as a tumor suppressor gene. Oncogene 23: 5941-5949.
67. Li Y, Luo L, Thomas DY, Kang CY. (1994). Control of expression, glycosylation, and secretion of HIV-1 gp120 by homologous and heterologous signal sequences. Virology 204: 266-278.
68. Liu SL, Miller AD. (2007). Oncogenic transformation by the jaagsiekte sheep retrovirus envelope protein. Oncogene 26: 789-801.
69. Lusher ME, Lindsey JC, Latif F, Pearson ADJ, Ellison DW, Clifford SC. (2002). Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development. Cancer Res 62: 5906-5911.
70. Marsit CJ, Kim DH, Liu M, Hinds PW, Wiencke JK, Nelson HH et al. (2005). Hypermethylation of RASSF1A and BLU tumor suppressor genes in non-small cell lung cancer: implications for tobacco smoking during adolescence. Int J Cancer 114: 219-223.
71. Michalowski MB, de Fraipont F, Michelland S, Entz-Werle N, Grill J, Pasquier B et al. (2006). Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet Cytogenet 166: 74-81.
72. Morris MR, Hesson LB, Wagner KJ, Morgan NV, Astuti D, Lees RD et al. (2003). Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma. Oncogene 22: 6794-6801.
73. Mullegger J, Lepperdinger G. (2002). Degradation of hyaluronan by a Hyal2-type hyaluronidase affects pattern formation of vitelline vessels during embryogenesis of Xenopus laevis. Mech Dev 111: 25-35.
74. Muller HM, Oberwalder M, Fiegl H, Morandell M, Goebel G, Zitt M et al. (2004). Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 363: 1283-1285.
75. Novak U, Stylli SS, Kaye AH, Lepperdinger G. (1999). Hyaluronidase-2 overexpression accelerates intracerebral but not subcutaneous tumor formation of murine astrocytoma cells. Cancer Res 59: 6246-6250.
76. Oh HJ, Lee KK, Song SJ, Jin MS, Song MS, Lee JH et al. (2006). Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res 66: 2562-2569.
77. Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang XF, Dammann R, Pfeifer GP et al. (2002). The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene 21: 1381-1390.
78. Pan ZG, Kashuba VI, Liu XQ, Shao JY, Zhang RH, Jiang JH et al. (2005). High frequency somatic mutations in RASSF1A in nasopharyngeal carcinoma. Cancer Biol Ther 4: 1116-1122.
79. Polesello C, Huelsmann S, Brown NH, Tapon N. (2006). The Drosophila RASSF homolog antagonizes the hippo pathway. Curr Biol 16: 2459-2465.
80. Praskova M, Khoklatchev A, Ortiz-Vega S, Avruch J. (2004). Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. Biochem J 381: 453-462.
81. Qiu GH, Tan LKS, Loh KS, Lim CY, Srivastava G, Tsai ST et al. (2004). The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress- responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. Oncogene 23: 4793-4806.
82. Rabizadeh S, Xavier RJ, Ishiguro K, Bernabeortiz J, Lopez-Ilasaca M, Khokhlatchev A et al. (2004). The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death. J Biol Chem 279: 29247-29254.
83. Rai SK, Duh FM, Vigdorovich V, Danilkovitch-Miagkova A, Lerman MI, Miller AD. (2001). Candidate tumor suppressor HYAL2 is a glycosylphosphatidylinositol (GPI)-anchored cell-surface receptor for jaagsiekte sheep retrovirus, the envelope protein of which mediates oncogenic transformation. Proc Natl Acad Sci USA 98: 4443-4448.
84. Riquelme E, Tang M, Baez S, Diaz A, Pruyas M, Wistuba II et al. (2007). Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma. Cancer Lett 250: 100-106.
85. Roche J, Boldog F, Robinson M, Robinson L, Varella-Garcia M, Swanton M et al. (1996). Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene 12: 1289-1297.
86. Scheel H, Hofmann K. (2003). A novel interaction motif, SARAH, connects three classes of tumor suppressor. Curr Biol 13: R899-R900.
87. Schenk PW, Brok M, Boersma AW, Brandsma JA, Den Dulk H, Burger H et al. (2003). Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell kill. Mol Pharmacol 64: 259-268.
88. Sekido Y, Ahmadian M, Wistuba, II, Latif F, Bader S, Wei MH et al. (1998). Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene 16: 3151-3157.
89. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N et al. (2006). A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 3: e486.
90. Shivakumar L, Minna J, Sakamaki T, Pestell R, White MA. (2002). The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol 22: 4309-4318.
91. Shuster S, Frost GI, Csoka AB, Formby B, Stern R. (2002). Hyaluronidase reduces human breast cancer xenografts in SCID mice. Int J Cancer 102: 192-197.
92. Song MS, Song SJ, Ayad NG, Chang JS, Lee JH, Hong HK et al. (2004). The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 6: 129-137.
93. Stern R. (2004). Hyaluronan catabolism: a new metabolic pathway. Eur J Cell Biol 83: 317-325.
94. Sundaresan V, Chung G, Heppell-Parton A, Xiong J, Grundy C, Roberts I et al. (1998). Homozygous deletions at 3p12 in breast and lung cancer. Oncogene 17: 1723-1729.
95. Tommasi S, Dammann R, Zhang ZQ, Wang Y, Liu LM, Tsark WM et al. (2005). Tumor susceptibility of Rassf1a knockout mice. Cancer Res 65: 92-98.
96. Toole BP. (2004). Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4: 528-539.
97. Toyota M, Ho C, Ohe-Toyota M, Baylin SB, Issa JP. (1999). Inactivation of CACNA1G, a T-type calcium channel gene, by aberrant methylation of its 5′ CpG island in human tumors. Cancer Res 59: 4535-4541.
98. Tsubaki M, Takeuchi F, Nakanishi N. (2005). Cytochrome b561 protein family: expanding roles and versatile transmembrane electron transfer abilities as predicted by a new classification system and protein sequence motif analyses. Biochim Biophys Acta 1753: 174-190.
99. Udabage L, Brownlee GR, Nilsson SK, Brown TJ. (2005). The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp Cell Res 310: 205-217.
100. Ueda K, Kawashima H, Ohtani S, Deng WG, Ravoori M, Bankson J et al. (2006). The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res 66: 9682-9690.
101. Uno F, Sasaki J, Nishizaki M, Carboni G, Xu K, Atkinson EN et al. (2004). Myristoylation of the fus1 protein is required for tumor suppression in human lung cancer cells. Cancer Res 64: 2969-2976.
102. van der Weyden L, Tachibana KK, Gonzalez MA, Adams DJ, Ng BL, Petty R et al. (2005). The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis. Mol Cell Biol 25: 8356-8367.
103. Vavvas D, Li X, Avruch J, Zhang XF. (1998). Identification of Nore1 as a potential Ras effector. J Biol Chem 273: 5439-5442.
104. Velasco G, Grkovic S, Ansieau S. (2006). New insights into BS69 functions. J Biol Chem 281: 16546-16550.
105. Vigdorovich V, Strong RK, Miller AD. (2005). Expression and characterization of a soluble, active form of the jaagsiekte sheep retrovirus receptor, Hyal2. J Virol 79: 79-86.
106. Vos MD, Dallol A, Eckfeld K, Allen NP, Donninger H, Hesson LB et al. (2006). The RASSF1A tumor suppressor activates Bax via MOAP-1. J Biol Chem 281: 4557-4563.
107. Vos MD, Ellis CA, Bell A, Birrer MJ, Clark GJ. (2000). Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem 275: 35669-35672.
108. Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ. (2003a). RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem 278: 28045-28051.
109. Vos MD, Martinez A, Elam C, Dallol A, Taylor BJ, Latif F et al. (2004). A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability. Cancer Res 64: 4244-4250.
110. Vos MD, Martinez A, Ellis CA, Vallecorsa T, Clark GJ. (2003b). The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung. J Biol Chem 278: 21938-21943.
111. Wan J, Zhang W, Wu L, Bai T, Zhang M, Lo KW et al. (2006). BS69, a specific adaptor in the latent membrane protein 1-mediated c-Jun N-terminal kinase pathway. Mol Cell Biol 26: 448-456.
112. Wei G, Schaffner AE, Baker KM, Mansky KC, Ostrowski MC. (2003). Ets-2 interacts with co-repressor BS69 to repress target gene expression. Anticancer Res 23: 2173-2178.
113. Wei MH, Latif F, Bader S, Kashuba V, Chen JY, Duh FM et al. (1996). Construction of a 600-kilobase cosmid clone contig and generation of a transcriptional map surrounding the lung cancer tumor suppressor gene (TSG) locus on human chromosome 3p21.3: progress toward the isolation of a lung cancer TSG. Cancer Res 56: 1487-1492.
114. Wistuba, II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L et al. (2000). High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 60: 1949-1960.
115. Yau WL, Lung HL, Zabarovsky ER, Lerman MI, Sham JS, Chua DT et al. (2006). Functional studies of the chromosome 3p21.3 candidate tumor suppressor gene BLU/ZMYND10 in nasopharyngeal carcinoma. Int J Cancer 119: 2821-2826.
116. Yi Lo PH, Chung Leung AC, Xiong W, Law S, Duh FM, Lerman MI et al. (2006). Expression of candidate chromosome 3p21.3 tumor suppressor genes and down-regulation of BLU in some esophageal squamous cell carcinomas. Cancer Lett 234: 184-192.
117. Zaahl MG, Merryweather-Clarke AT, Kotze MJ, van der Merwe S, Warnich L, Robson KJ. (2004). Analysis of genes implicated in iron regulation in individuals presenting with primary iron overload. Hum Genet 115: 409-417.
118. Zhang L, Underhill CB, Chen L. (1995). Hyaluronan on the surface of tumor cells is correlated with metastatic behavior. Cancer Res 55: 428-433.
119. Zhang Z, Sun D, Van do N, Tang A, Hu L, Huang G. (2007). Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Int J Cancer 120: 32-38.
120. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. (2001). Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61: 249-255.